olmesartan has been researched along with pravastatin in 15 studies
| Studies (olmesartan) | Trials (olmesartan) | Recent Studies (post-2010) (olmesartan) | Studies (pravastatin) | Trials (pravastatin) | Recent Studies (post-2010) (pravastatin) |
|---|---|---|---|---|---|
| 841 | 185 | 554 | 3,575 | 1,036 | 816 |
| Protein | Taxonomy | olmesartan (IC50) | pravastatin (IC50) |
|---|---|---|---|
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Homo sapiens (human) | 0.1452 | |
| Insulin receptor | Rattus norvegicus (Norway rat) | 0.0056 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.0056 | |
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Rattus norvegicus (Norway rat) | 0.0254 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 3.6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (53.33) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A | 1 |
| Amano, N; Maeda, K; Moriwaki, T; Nakakariya, M; Ono, M; Sugiyama, Y | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chang, NC; Chou, TF; Lee, TM; Lin, MS | 1 |
| Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Lai, ZF; Matsuba, S; Ogawa, H; Tanaka, T; Tokutomi, Y; Yamamoto, E; Yamashita, T | 1 |
| Havekes, LM; Jukema, JW; Kleemann, R; Kooistra, T; Princen, HM; van der Hoorn, JW | 1 |
| Chen, M; Ichiki, T; Imayama, I; Inanaga, K; Miyazaki, R; Ohtsubo, H; Sunagawa, K | 1 |
| David, S; Fliser, D; Haller, H; Kielstein, JT; Kümpers, P; Lukasz, A | 1 |
| Ishihara, Y; Kohno, M; Kosaka, H; Mizukawa, M; Noma, T; Obayashi, A; Ohmori, K; Yoshida, J; Yukiiri, K | 1 |
| Horiuchi, M; Inaba, S; Iwai, M; Kanno, H; Mogi, M; Nakaoka, H; Senba, I; Sone, H | 1 |
| David, S; Fliser, D; Haller, H; Kielstein, JT; Lorenzen, JM; Neunhöffer, H | 1 |
| Eldawoody, H; Kimura, N; Nakayama, T; Saito, A; Shimizu, H; Takahashi, A; Tominaga, T | 1 |
| Akishita, M; Iijima, K; Ito, Y; Ouchi, Y; Son, BK | 1 |
1 review(s) available for olmesartan and pravastatin
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
1 trial(s) available for olmesartan and pravastatin
| Article | Year |
|---|---|
Circulating angiopoietin-2 in essential hypertension: relation to atherosclerosis, vascular inflammation, and treatment with olmesartan/pravastatin.
Topics: Adult; Aged; Angiopoietin-2; Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; C-Reactive Protein; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Imidazoles; Male; Middle Aged; Pravastatin; Prospective Studies; Tetrazoles; Vasculitis | 2009 |
13 other study(ies) available for olmesartan and pravastatin
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
Topics: Glutathione; Pharmacology; Sulfur Radioisotopes | 2011 |
In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
Topics: Angiotensin Receptor Antagonists; Animals; beta-Lactams; Biliary Tract; Biological Transport; Cells, Cultured; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pharmaceutical Preparations; Rats; Rats, Sprague-Dawley; Topotecan | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Additive effects of combined blockade of AT1 receptor and HMG-CoA reductase on left ventricular remodeling in infarcted rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelin-1; Gene Expression Regulation; Heart Ventricles; Hemodynamics; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Imidazoles; Male; Myocardial Infarction; Pravastatin; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Tetrazoles; Ventricular Remodeling | 2006 |
Pravastatin enhances beneficial effects of olmesartan on vascular injury of salt-sensitive hypertensive rats, via pleiotropic effects.
Topics: Animals; Disease Models, Animal; Drug Interactions; Drug Therapy, Combination; Endothelium, Vascular; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Imidazoles; Nitric Oxide; Oxidation-Reduction; Oxidative Stress; Pravastatin; Rats; Rats, Inbred Dahl; Reference Values; Risk Factors; Sensitivity and Specificity; Sodium Chloride, Dietary; Tetrazoles; Vascular Diseases | 2007 |
Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3Leiden transgenic mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoprotein E3; Atherosclerosis; Blood Pressure; Collagen; Diet, Atherogenic; Drug Synergism; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Inflammation; Lipids; Macrophages; Mice; Mice, Transgenic; Monocytes; Muscle, Smooth, Vascular; Pravastatin; Recombinant Proteins; Serum Amyloid A Protein; T-Lymphocytes; Tetrazoles | 2007 |
Inhibition of balloon injury-induced neointimal formation by olmesartan and pravastatin in rats with insulin resistance.
Topics: Angioplasty, Balloon; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Carotid Artery Diseases; Carotid Artery Injuries; Carotid Artery, Common; Cell Count; Cell Proliferation; Fructose; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Immunohistochemistry; Insulin Resistance; Male; Pravastatin; Rats; Rats, Sprague-Dawley; Stem Cells; Tetrazoles | 2007 |
Effects of combined olmesartan and pravastatin on glucose intolerance and cardiovascular remodeling in a metabolic-syndrome model.
Topics: Adiponectin; Adipose Tissue, White; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Blood Pressure; Blotting, Western; Body Weight; Cardiovascular System; Drug Therapy, Combination; Eating; Glucose Intolerance; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Lipids; Male; Metabolic Syndrome; Nitric Oxide Synthase Type III; Oxidation-Reduction; Pravastatin; Rats; Rats, Inbred OLETF; RNA, Messenger; Superoxides; Tetrahydrofolate Dehydrogenase; Tetrazoles | 2009 |
Improvement of glucose intolerance by combination of pravastatin and olmesartan in type II diabetic KK-A(y) mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antimetabolites; Antioxidants; Blood Glucose; Cyclic N-Oxides; Deoxyglucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucose Intolerance; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Insulin; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Oxidative Stress; Pravastatin; Spin Labels; Tetrazoles | 2009 |
Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension--results from the EUTOPIA trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Biomarkers; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Imidazoles; Male; Middle Aged; Osteopontin; Pravastatin; Prospective Studies; Randomized Controlled Trials as Topic; Tetrazoles | 2010 |
Effect of olmesartan and pravastatin on experimental cerebral aneurysms in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cerebral Arteries; Circle of Willis; Corrosion Casting; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelial Cells; Hydralazine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Intracranial Aneurysm; Microscopy, Electron, Scanning; Pravastatin; Rats; Tetrazoles; Treatment Outcome; Vasodilator Agents | 2010 |
Pravastatin and olmesartan synergistically ameliorate renal failure-induced vascular calcification.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Blood Pressure; Calcinosis; Drug Synergism; Drug Therapy, Combination; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Male; Pravastatin; Rats; Rats, Wistar; Renal Insufficiency; Tetrazoles | 2014 |